LL-37
A human cathelicidin antimicrobial peptide studied in laboratory research; not FDA-approved.
What it is
LL-37 is the human body's own antimicrobial peptide — part of the innate immune system, produced in skin and immune cells, capable of disrupting bacterial membranes directly. As biology it is important and heavily studied.
As a product, it's a lab reagent being sold as a biohack. Research interest in antimicrobial peptides as future drugs is real, but LL-37 itself has complex, context-dependent roles — including in inflammation and autoimmunity — that make casual self-administration a genuinely strange bet. No human therapeutic program supports it.
What researchers have actually studied it for
Innate immune defense, wound biology and inflammation in laboratory research; a molecule of scientific interest, not a developed therapy.
How it works
The only human cathelicidin: a 37-amino-acid amphipathic helix that physically disrupts microbial membranes while separately signaling to immune cells — recruiting them, modulating inflammation, influencing wound biology. Its effects flip with concentration and context, which is exactly why 'supplementing' it is conceptually confused.
Where it came from
Cloned in 1995 during the antimicrobial-peptide wave that followed cecropin and defensin discoveries, LL-37 became one of immunology's most-studied molecules — thousands of papers spanning infection, wound healing, psoriasis and autoimmunity. Therapeutic development has focused on derivatives and topical concepts, none of which is the injectable vial online.
What the research record actually contains
- Vast basic-science literature on membrane disruption and immune signaling.
- Disease-association studies: elevated LL-37 activity in psoriasis, rosacea and some autoimmune states.
- Early exploratory work on topical derivatives (e.g. wound care) — no approved therapy, no systemic human program.
What's known about risks
Systemic self-administration has no human data, and the association of excess LL-37 activity with inflammatory skin disease is a standing caution the marketing never mentions. This is a molecule whose dose- and context-dependence is the central scientific finding about it.
Where it stands legally
No approved product anywhere; research-reagent channel only.
Worth asking a licensed provider
- 1.What infection or immune concern am I actually trying to address, and what's the evaluated route?
- 2.Am I aware elevated LL-37 activity is a feature of inflammatory diseases, not just defense?
- 3.If wound healing is the issue, what's the proper work-up?